A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Inclusion criteria

• Age ≥18 years old, both male and female;
• patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;
• Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;
• The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;
• Voluntary enrollment; good compliance and willingness to cooperate with follow-up.

Exclusion criteria

• Pregnant or lactating women;
• Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);
• Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);
• Patients who, in the judgment of the investigator, are not suitable for inclusion.